Document:

Joint
Venture Contract

    OF

    SUZHOU
ERYE PHARMACEUTICAL CO., LTD.

     

      
        

      

    

    
       

    

    

    Superseding
the Version Executed on June 16, 2005

    Amended
and Restated on October 21, 2009

    

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                
                                  
                                    
                                      
                                        
                                          
                                            
                                              
                                                	
                                                        CHAPTER
      I GENERAL

                                                      	
                                                        2

                                                      
	 	 
	
                                                        CHAPTER
      II PURPOSE, BUSINESS SCOPE AND SCALE OF THE JV COMPANY

                                                      	
                                                        2

                                                      
	 	 
	
                                                        CHAPTER
      III TOTAL INVESTMENT AND REGISTERED CAPITAL

                                                      	
                                                        3

                                                      
	 	 
	
                                                        CHAPTER
      IV LIABILITIES OF THE PARTIES

                                                      	
                                                        4

                                                      
	 	 
	
                                                        CHAPTER
      V BUSINESS OPERATION

                                                      	
                                                        6

                                                      
	 	 
	
                                                        CHAPTER
      VI BOARD OF DIRECTORS

                                                      	
                                                        7

                                                      
	 	 
	
                                                        CHAPTER
      VII OPERATION AND MANAGEMENT ORGANIZATION

                                                      	
                                                        8

                                                      
	 	 
	
                                                        CHAPTER
      VIII YARD AND PLANT

                                                      	
                                                        9

                                                      
	 	 
	
                                                        CHAPTER
      IX EMPLOYMENT MANAGEMENT

                                                      	
                                                        9

                                                      
	 	 
	
                                                        CHAPTER
      X FINANCE, ACCOUNTING AND AUDITING

                                                      	
                                                        9

                                                      
	 	 
	
                                                        CHAPTER
      XI DISTRIBUTION OF PROFITS

                                                      	
                                                        10

                                                      
	 	 
	
                                                        CHAPTER
      XII NEW PLANT CONSTRUCTION

                                                      	
                                                        10

                                                      
	 	 
	
                                                        CHAPTER
      XIII COOPERATION TERM AND ASSET DISPOSAL AFTER TERMINATION

                                                      	
                                                        12

                                                      
	 	 
	
                                                        CHAPTER
      XIV AMENDMENT, CHANGE AND CANCELLATION OF CONTRACT

                                                      	
                                                        12

                                                      
	 	 
	
                                                        CHAPTER
      XV LIABILITIES FOR DEFAULT

                                                      	
                                                        13

                                                      
	 	 
	
                                                        CHAPTER
      XVI DISPUTE RESOLUTION

                                                      	
                                                        13

                                                      
	 	 
	
                                                        CHAPTER
      XVII EFFECTIVENESS AND OTHERS

                                                      	
                                                        14

                                                      

                                              

                                            

                                          

                                        

                                      

                                    

                                  

                                

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

     

    
      
         

      

      
        - i
-

        
          

        

      

      
         

      

    

    This
Joint Venture Contract (this “Contract”)
is entered into by and between:

     

    
      
        	
                Party A:

              	
                Suzhou Erye Economy & Trade
      Co., Ltd.

              
	Registered
      Address:    	Tainan
      Road, Canglang District, Suzhou
	Legal
      Representative: 	Shi
      Mingsheng     Title:
      Chairman    Nationality:
      Chinese

      

    

                                   

    
      
        
          	
                  Party B

                	
                  China Biopharmaceuticals
      Holdings Inc.

                
	Legal
      Address:      	      
                  101
      East 52nd
      Street, New York, New York

                
	Legal
      Representative: 	Peng
      Mao    Title: CEO    Nationality:
      Canadian

        

      

          

    

     

    WHEREAS,

     

    (1)           Party
A is a limited liability company duly registered and established and validly
existing under the laws of the People’s Republic of China (the “PRC”), and
Party B is a limited liability company duly established and validly existing
under the laws of the State of Delaware of the United States of America (the
“U.S.”).

     

    (2)           NeoStem,
Inc. (“NeoStem”)
is a corporation duly established and validly existing under the laws of the
State of Delaware of the U.S., and Party B is a wholly-owned subsidiary of
NeoStem.

     

    (3)           Suzhou
Erye Pharmaceutical Co., Ltd. (the “JV
Company” or the “Subsisting
Company”) is a limited liability company duly registered and established
and validly existing under the laws of the PRC.

     

    (5)           To
further specify the rights and obligations of Party A and Party B, Party A and
Party B agree to enter into this Contract to supersede the original JV legal
documents by amending and restating all thereof so that the original JV legal
documents will have no further effect when this Contract becomes
effective.

     

    

     

    DEFINITIONS:

     

    (1)           “Subsistence-after-Split-off”
shall mean the status of the JV Company where it is split off on September [    ],
2009 according to a resolution of the Board of Directors of the JV
Company.  Specifically, the JV Company (the Subsisting Company) will
maintain business after the split-off and will carry on partial assets and all
liabilities (other than the liabilities related to the assets that are split
off), and, in the meanwhile, a new company (the “New
Company”) will be set up to carry on partial assets.  The
Subsisting Company has executed a Split-off Agreement with the New Company which
will become effective upon the change registration with the competent
administration of industry and commerce.

     

    
      
         

      

      
        - 1
-

        
          

        

      

      
         

      

    

    (2)           “Split-off
Date” shall mean the date of the change registration for the aforesaid
split-off, as approved by the PRC government, with the competent administration
of industry and commerce, being the first day as from which the Split-off
Agreement becomes effective pursuant to the PRC laws.

     

    (3)           “Relocation of the
JV Company” shall mean the construction plan for a new operation premises
already carried out by the JV Company, pursuant to which the JV Company will
purchase land and new equipment on the new yard (located at Huangdai Town,
Xiangcheng District, Suzhou) and build plants thereon, and remove its operating
activities from the old yard (859 Panxu Road, Suzhou) to the new yard after
obtaining the production permit from the government authority.

     

    (4)           “Control”
shall mean the activities of a party to influence the operation and decisions of
the other party, through holding more than fifty percent (50%) of the equity
interest, or being entitled to appoint or recommend more than fifty percent
(50%) of directors of the Board, or agreement or acceptance of authorization or
otherwise.  “Controlling
Person” or “Parent
Company” shall mean such controlling party.  The Control of a
third company by a Controlling Person through the controlled company shall be
deemed as a direct Control of such third company by the Controlling
Person.

     

    (5)           “Affiliate”
shall include the Parent Company controlling a party, any subsidiary under
control by such party or any company under the common control with such
party.

     

     

    CHAPTER I

    GENERAL

     

    Article
1                      Subject
to the Law of the People’s
Republic of China on Sino-Foreign Equity Joint Venter Enterprises and
other applicable laws and regulations of the PRC, Party A and Party B agree to
carry on the operation of Suzhou Erye Pharmaceutical Co., Ltd. as a joint
venture (the “JV
Company”).  The name of the JV Company is “Suzhou Erye
Pharmaceutical Co., Ltd.” in English and “苏州二叶制药有限公司” in
Chinese.

     

    Article
2                      The
legal address of the JV Company is at 859 Panxu Road, Canglang District, Suzhou,
Jiangsu Province.

     

    Article
3                      Any
and all of the activities of the JV Company shall be in compliance with the laws
and regulations of the PRC and subject to the jurisdiction and protection of the
PRC law.

     

     

    CHAPTER
II

    PURPOSE,
BUSINESS SCOPE AND SCALE OF THE JV COMPANY

     

    Article
4                      The
purpose of the JV Company is to develop an internationally leading company by
mutual efforts based on the desire of strengthening economic cooperation and
technical communications.  Both Party A and Party B will try to
achieve the satisfactory economic benefits through scientific operation and
management, and explore and develop the business of the JV Company in the spirit
of mutual understanding and mutual cooperation.

     

    
      
         

      

      
        - 2
-

        
          

        

      

      
         

      

    

    Article
5                      The
business scope of the JV Company covers the production and sale
of  sterile injection powder (penicillin and cefa-), hard capsule,
crude drug (including penicillin) and aluminum cover of injection bottle, the
operation of export of antibiotic active compound and antibiotic series sterile
injection powder and capsule manufactured by the JV Company and of technologies
related thereto, the operation of export of raw and auxiliary materials,
machinery equipment, instrumentations, fittings and components, and technologies
necessary for the production and scientific research of the JV Company
(excluding products and technologies the operation of which is restricted or the
import/export of which is prohibited by the State), and the operation of the
business of processing with imported materials and the business of processing
according to samples, assembling parts conducting supplied by investor or
clients and/or conducting compensation trade.

     

    Article
6                      The
scale of the JV Company’s production shall range from RMB200,000,000 to
300,000,000 as to its annual sales revenue, and the scale will be expanded or
adjusted gradually based on the market status.

    

     

    CHAPTER III

    TOTAL
INVESTMENT AND REGISTERED CAPITAL

     

    Article
7                      The
amount of the total investment of the JV Company, as a subsisting company upon
the Subsistence-after-Split-off, shall be changed to Renminbi Thirty Two Million
Two Hundred and Forty Thousand yuan (RMB32,240,000) from the
original Renminbi Forty Million Eight Hundred and Sixteen Thousand Four Hundred
yuan
(RMB40,816,400).

     

    Article
8                      The
amount of the registered capital of the JV Company, upon the
Subsistence-after-Split-off, shall be Renminbi Sixteen Million One Hundred and
Twenty Thousand yuan
(RMB16,120,000) and its paid-in capital then shall be Renminbi Sixteen Million
One Hundred and Twenty Thousand yuan
(RMB16,120,000).

     

    
      	
                  1.      

            	
              The
      amount of the registered capital of the JV Company before the aforesaid
      split-off, being Renminbi Twenty Million Four Hundred Thousand yuan (RMB20,400,000),
      has been fully paid up, among
which,

            

    

     

    A.           an
amount of Renminbi Ten Million yuan (RMB10,000,000) was
subscribed by the original 38 Chinese individual shareholders upon the
establishment of the JV Company on June 6, 2003 as a PRC domestic
company.  Party A became a shareholder of the JV Company by purchasing
such amount from those original 38 Chinese individual shareholders on May 19,
2008.

     

    B.           an
amount of Renminbi Ten Million Four Hundred Thousand yuan (RMB10,400,000) was
injected by CBH in two installments to increase the investment, respectively, in
February of 2006 and April of 2006, totaling Two Million Two Hundred Thousand US
dollars (US$2,200,000),  equal to Renminbi Eighteen Million Two
Hundred and Eight Thousand Three Hundred yuan (RMB18,208,300) as
converted at the then exchange rate, in which the amount of Renminbi Ten Million
Four Hundred Thousand yuan (RMB10,400,000) has been
confirmed as the registered capital of the JV Company and the residual of which
is accounted as capital surplus under its capital reserve.

     

    
      
         

      

      
        - 3
-

        
          

        

      

      
         

      

    

    
      	
                  2.      

            	
              Since
      the JV Company has been split off, the JV Company, as a subsisting
      company, sees a reduction in the amount of its registered capital from
      Renminbi Twenty Million Four Hundred Thousand yuan (RMB20,400,000)
      down to Renminbi Sixteen Million One Hundred and Twenty Thousand yuan (RMB16,120,000),
      among which Party A is holding its registered capital of Renminbi Seven
      Million Eight Hundred and Ninety Eight Thousand Eight Thousand yuan (RMB7,898,800) and
      Party B is holding its registered capital of Renminbi Eight Million Two
      Hundred and Twenty One Thousand Two Hundred yuan
      (RMB8,221,200).  Party A and Party B have paid up their
      subscribed amounts of registered capital
  respectively.

            

    

     

    Article
9                      When
this Contract becomes effective, Party A holds 49% of the total registered
capital of the JV Company and Party B holds 51% of the total registered capital
of the JV Company.

     

    Article
10                    If
a party hereto (the “Transferring
Party”) intends to transfer its equity interest in the JV Company to a
third party, such Transferring Party must first offer such equity interest to
the other party hereto (the “Non-Transferring
Party”) in a writing (the “Offer”)
setting forth the terms and conditions for the interest to be
transferred.  If the Non-Transferring Party refuses the Offer, or
fails to accept the Offer within 90 days (the “Consideration
Period”), or fails to close on the Offer within 45 days (the “Closing
Period”) after accepting the Offer, the Transferring Party shall be free
to offer, within 90 days commencing from the earliest of such refusal, the end
of the Consideration Period or the end of the Closing Period, its equity
interest to any third party, and close the transfer within 45 days after such
offer is accepted, on such terms and conditions as can be verified by the
Non-Transferring Party to be no more favorable than those for the Offer to the
Non-Transferring Party.

     

    The
transfer of its equity interest by either party hereto to any other third party
shall mean such circumstance that causes the change of the actual Controlling
Person of the Transferring Party, including but not limited to:

     

    1.           Either
party hereto directly transfers its equity interest in the JV Company to any
third party, or otherwise disposes of such equity interest to the effect that
such equity interest would be actually transferred; or

     

    2.           The
actual Controlling Person of either party hereto holding more than 50% of the
equity interest of such party changes unless such Controlling Person is a public
company.

     

     

    CHAPTER IV

    LIABILITIES
OF THE PARTIES

     

    Article
11                      Either
party hereto represents and warrants to the other party hereto as
follows:

     

    
      
         

      

      
        - 4
-

        
          

        

      

      
         

      

    

    1.           It
has any and all of the civil rights and capacities necessary to the execution
and performance of this Contract which will not violate or breach any and all of
the legal documents, including but not limited to the articles of association,
contracts and agreements, binding on it.

     

    2.           It
has taken or will take any and all of the necessary actions in order to obtain
any and all of the consents, approvals, authorizations and permits required by
the execution and performance of this Contract.

     

    3.           It
will make its best efforts to cooperate closely with the other party hereto on
reliance of the doctrines of good faith, pragmatism and responsibility so as to
cause this Contract to be performed in a sound and smooth manner, and strictly
comply with any and all of the principles set out herein and commit nothing that
may impair the performance of this Contract.

     

    4.           As
of the date on which this Contract becomes effective, it has not, and undertakes
that none of its Affiliates has, individually or jointly with any third party,
engaged or participated in, or owned any interests or benefits in, any business
of chemical drugs that directly competes with the JV Company.

     

    5.           Either
party hereto confirms with the other party hereto that the equity interest of
the other party hereto in the JV Company is legitimate and valid and that it
will use its best efforts to defend the shareholder’s interests of the other
party hereto.

     

    Article
12             Party
A represents and warrants as follows:

     

    1.           Any
and all of the materials that have been or will be furnished to Party B by it
shall be true, complete, correct and not misleading.

     

    2.           It
has obtained any requisite authority, permit, authorization, license and
consent, including but not limited to the business license issued by the
competent administration of industry and commerce, necessary to carry on its
business operation, and its operation has not exceeded the approved business
scope and provisions of its articles of association.

     

    Article
13             Party
B represents and warrants as follows:

     

    1.           Any
and all of the information disclosed to Party A by it is true, timely and
complete.

     

    2.           It
shall not make any claim over or challenge any agreement entered into by the JV
Company as of the date hereof so long as such agreement has been disclosed
pursuant to the U.S. securities law or was entered into in the ordinary course
of business with normal commercial terms.

     

    3.           It
has informed NeoStem of the contents hereof.  NeoStem irrevocably
undertakes to guarantee its obligations and liabilities hereunder, and the
undertaking letter issued by NeoStem for such purpose in the form attached
hereto shall constitute an integral part of this Contract.

     

    
      
         

      

      
        - 5
-

        
          

        

      

      
         

      

    

    4.           Prior
to the investment by it in any chemical drug manufacturing company that competes
directly with the business of the JV Company, it must obtain the consent from
the JV Company.  It shall consult with the JV Company prior to
introducing any new chemical drug into the PRC with respect to whether the same
can be produced in a more cost-saving or efficient manner by the JV
Company.

    

     

    CHAPTER
V

    BUSINESS
OPERATION

     

    Article
14                      Any
business conducted by the JV Company shall be decided and carried out by the
Board of Directors of the JV Company.

     

    Party B
will be entitled to, with a reasonable prior notice to the JV Company,
periodically send its representatives to visit the JV Company and consult with
the senior management of the JV Company with respect to operation, financial
conditions, strategy and other similar issues.

     

    Article
15                      The
JV Company shall mainly purchase the raw and auxiliary materials necessary for
its production in the PRC domestic market, and sell most of its finished
products in the PRC domestic market, with a small amount sold
abroad.

     

    Article
16                      The
JV Company shall continue to use the existing production equipment and
technologies to conduct its business.  If the purchase of any
additional equipments or technologies becomes necessary, the priority will be
given to the PRC domestic market.

     

    Article
17                      Should
NeoStem succeed in its development of stem cell medicine, Party B shall, if
permitted by the applicable PRC law, be responsible for introducing such
medicine into the PRC, in which case the JV Company shall enjoy the priority
right of production and sale of the same in the PRC, subject, however, to the
capability of the JV Company in such production and sales activities, taking
into consideration factors including the competitive costs, time-to-market,
quality, stability and other similar aspects of the same.

     

    Article
18                      Party
B or NeoStem shall from time to time study the feasibility of introducing
certain commercially potential patented medicine into the PRC under the
appropriate market conditions, based on the existing resources and general
market circumstances.  In the event Party B or NeoStem fails to
support the JV Company in terms of products, Party B or NeoStem shall, subject
to the approval of their respective board of directors, provide the JV Company
with the R&D funds support based on its future demands and business
development.

     

    Article
19                      Since
the integration of the PRC domestic pharmaceutical industry provides a new
opportunity, Party A will seize any chance to seek and land some merger and/or
acquisition projects favorable for the development of the JV Company pursuant to
the guidelines and standards mutually agreed by Party A and Party B or
NeoStem.  Party B undertakes that NeoStem will conduct a due diligence
investigation towards the target acquisition together with Party A, and NeoStem
or Party B will, subject to the approval of NeoStem’s board of directors,
provide capital or equity support therefor.

     

    
      
         

      

      
        - 6
-

        
          

        

      

      
         

      

    

     

    CHAPTER
VI

    BOARD
OF DIRECTORS

     

    Article
20             The
number of the members of the Board of Directors of the JV Company shall be
reduced from seven (7) to five (5), among whom two (2) Directors shall be
appointed by Party A and three (3) Directors shall be appointed by Party
B.  One of the Directors appointed by Party B shall be the director on
the board of directors of NeoStem appointed by Party A (and such Director shall
represent the interests of Party B in the discharge of his or her duties as a
Director).  The tenure of each Director shall be four (4) years,
renewable upon re-appointment consecutively.

     

    The
Chairman of the JV Company shall be the Director appointed by Party A to the
Board of Directors and  shall be the legal representative of the JV
Company.

     

    The CFO
of the JV Company shall be appointed by Party A.

     

    Article
21             The
Board of Directors shall be the highest authority of the JV Company and shall
decide any and all of the major issues of the JV Company.

     

    With
regard to any of the following matters, no resolution may be adopted without the
affirmative voting of more than seventy five percent (75%) of the entire members
of the Board of Directors:

     

    1.           Disposition
of any and all of the material assets of the JV Company;

     

    2.           Change
of more than 50% of equity interest;

     

    3.           Change
of more than a half of the entire Directors, in the accumulative aggregate,
within any consecutive twenty four (24) months, excluding any change due to
retirement, injury, illness, death, voluntary resignation, termination of
employment or any other similar cause;

     

    4.           Decision
on the material strategy of operation and development of the JV Company;
and

     

    5.           Any
related-party transaction between the JV Company and its shareholders and/or
Affiliates.

     

    With
regard to any of the following matters, no resolution may be adopted without the
unanimous consensus of all the Directors present at a board
meeting:

     

    1.           Amendment
to the Articles of Association of the JV Company;

     

    2.           Termination
or dissolution of the JV Company;

     

    3.           Increase
or reduction of the registered capital of the JV Company; and

     

    
      
         

      

      
        - 7
-

        
          

        

      

      
         

      

    

    4.           Merger
or divestiture of the JV Company.

     

    Except
the major issues set forth above, decisions with respect to all other issues
required voting of the Directors may be adopted by more than half of the entire
members of Board of Directors.

     

    Article
22              The
Board of Directors shall meet at least one (1) time during each year, and shall
be convened and presided over by the Chairman or, if the Chairman is incapable
of doing so, by a Director authorized by the Chairman.  Upon the
request of any two Directors, the Chairman shall convene an interim meeting of
the Board of Directors.  Any Director may attend any Board meeting
telephonically.

     

    Article
23               The
quorum for any meeting of the Board of Directors shall be at least four (4)
Directors.

     

    If a
Director is unable to attend a meeting of the Board of Directors, he or she may
issue a proxy and entrust a representative to attend the meeting and vote on his
or her behalf, whose attendance shall be deemed the same as attendance by him or
her.

     

    The
minutes of any and all of the meetings of the Board of Directors shall be signed
by all the Directors present at the meeting before kept into files.

     

    A meeting
of the Board of Directors shall generally be held at the place of legal address
of the JV Company.

     

     

    CHAPTER VII

    OPERATION
AND MANAGEMENT ORGANIZATION

     

    Article
24               The
JV Company shall establish its management structure responsible for its
day-to-day corporate management.  The management structure shall
consist of one (1) General Manager who shall be engaged by the Board of
Directors for a tenure of four (4) years, renewable upon re-assignment
consecutively.

     

    Article
25               The
General Manager shall be responsible for carrying out any and all of the
resolutions of the Board of Directors and organizing and directing the
day-to-day management of the JV Company.  Within the authorization by
the Board of Directors, the General Manager shall act on behalf of the JV
Company, hire or dismiss any employees under his or her level, and exercise such
other powers as granted by the Board of Directors.

     

    Article
26                The
Chairman or any Director may concurrently serve as General Manager or other
senior officer of the JV Company upon the engagement by the Board of
Directors.  In the event the General Manager or any of other senior
officers practices graft or commits a gross neglect of duty, the Board of
Directors may make a resolution at any time to dismiss and impose a necessary
punishment on him or her.

     

    
      
         

      

      
        - 8
-

        
          

        

      

      
         

      

    

     

    CHAPTER
VIII

    YARD
AND PLANT

     

    Article
27                 With
respect to the old yard of the JV Company in use and located at 859 Panxu Road,
Suzhou, the land area is 45,024.2 square meters and construction area is
33,492.75 square meters.  The land use right to and all the buildings
on such old yard have been split off to the New Company because of the
occurrence of the Subsistence-after-Split-off to the JV Company which will
lease, at a token price, the land and plant buildings (i.e. the old yard) from
the New Company, and maintain the original operation and businesses
unchanged.

     

    The land
area of the new yard of the JV Company located at Huangdai Town, Xiangcheng
District, Suzhou is 107,385.6 square meters, while buildings and plants thereon
are now under construction.  The land use right to and the buildings
on such new yard belong to and are possessed by the JV Company.

     

    

     

    CHAPTER
IX

    EMPLOYMENT
MANAGEMENT

     

    Article
28                 The
JV Company undertakes that it will continue to employ each and every former
employee before joint venture.  Any recruitment and dismissal of the
employees of the JV Company shall be reviewed and determined by the Board
according to the PRC Labor Law, the PRC Labor Contract Law and other applicable
PRC regulations. The JV Company and the trade union thereof shall collectively
or with individual separately enter into labor contracts.  The labor
contract shall, once duly executed, be filed with the competent local labor
administration authority.

     

    Article
29                  All
payments in connection with salaries, benefits and labor insurances of the
employees of the JV Company shall be made pursuant to the PRC Labor Law and
other applicable PRC regulations.

     

    

     

    CHAPTER
X

    FINANCE,
ACCOUNTING AND AUDITING

     

    Article
30                 Any
fiscal year of the JV Company shall commence on January 1st and end
on December 31st of the
same year.  Any and all of the vouchers, bills, statements and books
shall be prepared in Chinese.  The JV Company shall use Renminbi as
its standard bookkeeping currency.

     

    The JV
Company shall, in most cases, make settlement of accounts monthly and final
settlement at the end of each year.  All financial statements shall be
prepared according to the accounting principles of the PRC.  The JV
Company shall, on the annual basis, deliver to Party B the complete audited
financial statements.

     

    Party A
shall use its efforts to cause the JV Company to take any and all of the
necessary actions and provide any and all of the necessary information of the JV
Company to NeoStem so that NeoStem can timely fulfill its reporting obligations
under the U.S. securities law, including compliance with the accounting rules of
the Securities and Exchange Commission of the U.S.  Party A shall
support NeoStem’s corporate development strategy and compliance with the U.S.
securities law.

     

    
      
         

      

      
        - 9
-

        
          

        

      

      
         

      

    

    Article
31                      A
PRC CPA shall be retained for financial auditing and shall report the results to
the Board of Directors and the General Manager.

     

    

    CHAPTER
XI

    DISTRIBUTION
OF PROFITS

     

    Article
32                      The
JV Company shall go through formalities in respect of reduction, exemption and
payment of income tax imposed upon its profits according to the Law of the People’s Republic of
China of Enterprise Income Taxes and regulations related
thereto.  After deduction of public reserves from the profits for a
given year, the Board of Directors shall make bonus distribution plan based on
the operation of that year.

     

    Article
33                      The
dividend distributions to the shareholders shall be made in proportion to the
shareholders’ equity, unless otherwise prescribed herein.

     

    

     

    CHAPTER
XII

    NEW
PLANT CONSTRUCTION

     

    Article
34                      For
the purpose of a smooth completion of the relocation of the JV Company, Party B
agrees to continue to be responsible for costs for such relocation, which is
only limited to, and will not be responsible for any cost
exceeding:

     

    1.           Profit distribution prior to the
Split-off Date

     

    Any and
all of the undistributed profits as of the Split-off Date (subject to the
statements audited under the PRC accounting principles) shall be used for
dividend distribution.  Party A and Party B agree that such dividend
distribution shall be made by the end of March of 2010 and shall instruct the
Directors to execute a board resolution authorizing such dividend
distribution.  Specifically,

     

    1.1           49%
of such dividend distribution (after tax) shall be allocated to Party A who
shall, upon its receipt of the same, loan back to the JV Company who shall later
repay Party A gradually following the completion of the construction of the new
plant (together with interest thereon, computed at the then applicable standard
interest rate for Renminbi loans by financial institutions announced by the
People’s Bank of China).  Such loan by Party A shall not be deemed as
the performance by Party B of part of its obligation to fund the relocation of
the JV Company.

     

    
      
         

      

      
        - 10
-

        
          

        

      

      
         

      

    

    1.2           51%
of such dividend distribution (after tax) shall be allocated directly to the JV
Company as the new plant construction fund.  Party A and Party B agree
to characterize such fund as the capital surplus for such 51% interest in the JV
Company as subscribed by Party B, to be recorded under the capital reserve entry
of the JV Company (subject to the auditing opinion of a PRC
accountant).  If such 51% dividend distribution results in any tax
liability onto Party B, the JV Company shall allocate a sufficient dividend in
cash to Party B to cover such tax liability.

     

    2.           Profit distribution in three years
following the Split-off Date

     

    For a
three (3) years period commencing on the first day of the first fiscal quarter
after this Contract becomes effective and ending on the third anniversary
thereof, the operating net profit of the JV company shall be distributed fully
as a dividend distributed annually within 90 days after the prior fiscal year
ends.  Specifically,

     

    2.1           49%
of the dividend distribution (after tax) shall be allocated to Party A who
shall, upon its receipt of the same, loan back to the JV Company who shall later
repay Party A gradually following the completion of the construction of the new
plant (together with interest thereon, computed at the then applicable standard
interest rate for Renminbi loans by financial institutions announced by the
People’s Bank of China).  Such loan by Party A shall not be deemed as
the performance by Party B of part of its obligation to fund the relocation of
the JV Company.

     

    2.2           
45% of the dividend distribution (after tax) shall be allocated directly to the
JV Company as part of the new plant construction fund. Party A and Party B agree
to characterize such fund as the capital surplus for such 51% interest in the JV
Company as subscribed by Party B, to be recorded under the capital reserve entry
of the JV Company (subject to the auditing opinion of a PRC
accountant).  If such 45% dividend distribution results in any tax
liability onto Party B, the JV Company shall allocate a sufficient dividend in
cash to Party B to cover such tax liability.

     

    2.3           6%
of the dividend distribution (after tax withholding) shall be allocated directly
to Party B for the direct purpose of NeoStem’s operating expenses.

     

    2.4           In
the event of the sale of all of the assets of the JV Company or liquidation of
the JV Company, Party B shall be entitled to receive the return of such capital
surplus before any distribution of the JV Company’s assets is made based upon
the shareholding percentages of the shareholders.  Upon an initial
public offering of the JV Company which raises at least Renminbi Fifty Million
yuan (RMB50,000,000),
to the extent permitted by the applicable PRC law and accounting principles and
approved by the Board of Directors, Party B shall be entitled to receive the
return of such capital surplus.

     

    
      
         

      

      
        - 11
-

        
          

        

      

      
         

      

    

    2.5           Party
A and Party B shall respectively instruct their Directors in the JV Company to
execute a board resolution authorizing such dividend distribution.

     

    Article
35               Party
A undertakes that, after the implementation of Article 34, if the JV Company is
still in need of fund, the JV Company may finance itself through
loans.  Party A shall exert its best efforts to assist the JV Company
in raising funds and shall endeavor to complete the relocation of the JV Company
within three (3) years.   Further, the land, buildings, equipment
and other assets of the new plant of the JV Company shall belong to and be
possessed by the JV Company and shall be recorded into the balance sheet of the
JV Company.

     

    Article
36                Party
B undertakes that, during the course of the relocation to the new plant, it
shall use its efforts to attempt to provide certain loan assistance to the JV
Company.

     

    Article
37                Relocation

     

    After the
new yard of the JV Company (located at Huangdai Town, Xiangcheng District,
Suzhou) meet such conditions precedent to its production as specified by the
competent governmental authority or authorities and any and all of the equipment
for its operation have been conveyed into the new yard and can run completely,
the Subsisting Company must use its best efforts to promptly terminate its
operating activities in the old yard, and the lease between the JV Company and
the New Company shall then terminate.

     

    

     

    CHAPTER
XIII

    COOPERATION
TERM AND ASSET DISPOSAL AFTER TERMINATION

     

    Article
38               The
cooperation term of the JV Company shall be twenty five (25) years, and the
issuance date of the JV Company’s business license shall be deemed as its
establishment date.

     

    Article
39               The
JV Company shall enter into liquidation according to law after the expiration or
upon any prior termination of cooperation term.  After the
verification of the liquidated finance by accounting firm, the remaining assets
shall be allocated or assumed by Party A and Party B pro rata in proportion to
their equity interests in the JV Company.

    

     

    CHAPTER
XIV

    AMENDMENT,
CHANGE AND CANCELLATION OF CONTRACT

     

    Article
40                      Any
amendment to this Contract and/or the exhibits hereto shall not become effective
unless and until Party A and Party B have executed a supplementary contract with
respect thereof.

     

    Article
41                      Upon
the proposal initiated by either Party and the unanimous consensus adopted at a
meeting of the Board of Directors, the cooperation term may be extended by
filing to the competent foreign economic and trade cooperation bureau or its
entrusted approval agency six (6) months prior to the expiration
thereof.

     

    
      
         

      

      
        - 12
-

        
          

        

      

      
         

      

    

    Article
42                      This
Contract can, after Party A and Party B have reached an agreement to the
aftermath matters, be early terminated for any of the following
reasons:

     

    1.           Either
party hereto proposes to terminate this Contract and such proposal has been
agreed by the two parties;

     

    2.           The
performance of this Contract become impossible because of such a force majeure
event as earthquake, typhoon, flood, fire or warfare which is unforeseeable and
the consequence of which cannot be prevented or is unavoidable;

     

    3.           The
JV Company has been suffering losses for consecutive years and is incapable of
continuing its operation; and

     

    4.           The
JV Company is unable to meet the sales scale set forth herein due to failure by
either party hereto to perform its obligations under, or its violation of, this
Contract or the Articles of Association.

     

     

    CHAPTER
XV

    LIABILITIES
FOR DEFAULT

     

    Article
43                      If
the JV Company has suffered any damages due to any fault of either party hereto,
such defaulting party shall indemnify the JV Company for the losses as a result
thereof.

     

    Article
44                      If
this Contract and/or the exhibits hereto shall become non-performable or cannot
be performed to its full extent due to any fault of either party hereto, such
defaulting party shall assume such liabilities for default and indemnify
relevant losses thereof.  If both Party A and Party B have been in
default, Party A and Party B shall assume their respective and separate
liabilities and indemnify relevant losses in light of the actual
circumstances.

     

    

     

    CHAPTER
XVI

     

    DISPUTE
RESOLUTION

     

    Article
45                      If
there is any dispute arising out of or in connection with this Contract, Party A
and Party B shall resolve such dispute through amicable negotiations, failing
which the dispute shall be submitted to China International Economic and Trade
Arbitration Commission for arbitration in Beijing in accordance with its
arbitration procedure and relevant rules.  Such arbitral award is
final and binding upon Party A and Party B.  The arbitration fees
shall be borne by the party hereto who loses the arbitration.

     

    Article
46                      During
the course of arbitration, except for the provisions hereof that are in dispute
and under arbitration, this Contract shall continue to be performed to the
effect that such disputed provisions shall not affect the normal operation of
the JV Company.

     

    
      
         

      

      
        - 13
-

        
          

        

      

      
         

      

    

    CHAPTER
XVII

    EFFECTIVENESS
AND OTHERS

     

    Article
47                      This
Contract shall be approved by the Ministry of Commerce of the PRC or its branch
offices and shall not become effective unless and until the date on which such
approval certificate has been obtained.

     

    Article
48                      The
ancillary agreements entered into in accordance with the principles set forth in
this Contract shall constitute an integral part of this
Contract.  Party A and Party B shall cooperate with each other to
amend the Articles of Association of the JV Company to reflect the terms of this
Contract as hereby amended.

     

    Article
49                      The
execution, validity, interpretation, performance and the dispute resolution of
this Contract shall be governed by the laws of the PRC.

     

    Article
50                      Such
legal addresses of Party A and Party B as set forth in this Contract shall be
their respective communication addresses to which the written documents to each
party hereto shall be addressed and shall be deemed delivered if so
addressed.

     

    Article
51                      This
Contract is made in Chinese into ten (10) originals, with Party A and Party B
each holding two (2) of them.  This Contract can be made into several
counterparts to be used for filing with the competent governmental
authorities.

     

    Article
52                      This
Contract is duly executed by the legal or authorized representatives of Party A
and Party B respectively on October [    ],
2009.

     

    [THE
REMAINING OF THIS PAGE IS INTENTIONALLY LEFT BLANK.]

     

    
      
         

      

      
        - 14
-

        
          

        

      

      
         

      

    

    (Execution Page of the Joint Venture
Contract of Suzhou Erye Pharmaceutical Co., Ltd.)

    

     

    
      	      
              For
      and on behalf of 

              Party
      A: Suzhou Erye Economy
      & Trade Co., Ltd.

               

              By: _________________________

              Shi
      Mingsheng, Chairman

              

              

              For
      and on behalf of 

              Party
      B: China
      Biopharmaceuticals Holdings Inc.

               

              By:___________________________

              Peng
      Mao, President

            	 
      
              )

              )

              )

              )

              )

              

              

              )

              )

              )

              )

              )

            

    

     

     

    
      
         

      

      
        - 15
-

        
          

        

      

      
         

      

    

    Undertaking

     

    NeoStem,
Inc. (“NeoStem”)
is a corporation duly established and validly existing under the laws of the
State of Delaware of the U.S.

     

    WHEREAS,

     

    NeoStem’s
wholly owned subsidiary China Biopharmaceuticals Holdings Inc. (“CBH”) and
Suzhou Erye Economic and Trade Co., Ltd. (“EET”) have
entered into a Joint Venture Contract of Suzhou Erye Pharmaceutical Co., Ltd.
(the “JV
Contract”) on October [    ],
2009.

     

    NOW,
THEREFORE NeoStem hereby undertakes:

     

    1.           THAT
NeoStem fully understands and absolutely agrees to the whole content of the JV
Contract;

     

    2.           THAT
CBH has obtained NeoStem’s necessary authorization to execute the JV
Contract;

     

    3.           THAT
CBH’s obligations and liabilities under the JV Contract shall be deemed the
obligations and liabilities of NeoStem who shall undertake to provide an
irrevocable guarantee for such joint liability;

     

    4.           THAT,
in accordance with the PRC law, the obligations and liabilities assumed by CBH
as a shareholder of Suzhou Erye Pharmaceutical Co., Ltd. shall be deemed to be
NeoStem’s obligations and liabilities for which NeoStem shall undertake to
provide an irrevocable guarantee;

     

    5.           THAT
NeoStem’s performance of its undertakings contained herein shall constitute the
consideration of EET’s performance of its obligations under the JV Contract, and
shall remain effective and irrevocable throughout the validity ofthe JV
Contract, and, if the JV Contract becomes invalid or terminates, this
Undertaking shall be canceled in accordance with any supplementary covenant by
and between NeoStem and EET;

     

    6.           THAT
NeoStem shall be entitled to the rights and benefits to which CBH is entitled to
under the JV Contract or should be entitled to under any other document relating
to the JV Company to which CBH is a party, provided that such rights and
benefits may not be enjoyed by CBH in a duplicative manner; and

     

    7.           THAT
this Undertaking, as part of the JV Contract, shall be governed by the PRC
law.

    
      

       

      
        
          	      
                        
                    For
      and on behalf of  

                    NeoStem,
      Inc. 

                     

                    By:  ___________________

                    Date:
      October [    ],
      2009

                  

                	      
                  )

                  )

                  )

                  )

                  )

                

        

      

       

      
        
           

        

        
          - 16
-EMPLOYMENT
AGREEMENT

    

    

    EMPLOYMENT AGREEMENT, dated as of
November 19, 2009 by and between NeoStem, Inc. (the “Company”) and Christopher
Duignan (the “Employee”).

    

    W I T N E S S E T
H:

    

    WHEREAS, the Company wishes for
Employee to serve as its Vice President, Finance and Employee agrees to so serve
on the terms hereinafter set forth.

    

    NOW THEREFORE, in consideration of the
mutual covenants herein contained, the parties hereto hereby agree as
follows:

    

    Section 1.  Employment.  The Company
agrees to employ the Employee, and the Employee agrees to be employed by the
Company, upon the terms and conditions hereinafter provided, for a period
commencing on November 30, 2009 (the “Commencement Date”) and, subject to
earlier termination pursuant to Section 5 hereof, continuing until the second
(2nd) anniversary of the Commencement Date (the “Term”).  The Employee
hereby represents and warrants that he has the legal capacity to execute and
perform this Agreement, and that its execution and performance by him will not
violate the terms of any existing agreement or understanding to which the
Employee is a party.

    

    Section 2.  Responsibilities. During the Term, the
Employee agrees to serve as Vice President, Finance.  It is agreed
that commencing as of February 15, 2009, Employee shall commence serving as
Employer’s Principal Accounting Officer, subject to the  prior
approval of the Company’s Board of Directors. Such position shall have such
duties as assigned to Employee from time to time by the Chief Executive Officer
of the Company, and which she considers to be appropriate for such
position.

    

    During
the Term, and except for reasonable vacation periods pursuant to the Company’s
policies, the Employee shall devote substantially all of his business time,
attention, skill and efforts exclusively to the business and affairs of the
Company and its subsidiaries and affiliates.  Employee shall be based
in or around New York, NY; however, it is understood that reasonable travel
shall be required from time to time.

    

    Section 3.  Compensation.  For all services
rendered by the Employee in any capacity required hereunder during the Term, the
Employee shall be compensated as follows:

    

    (a)           The
Company shall pay the Employee a fixed annual salary equal to $168,000 (the
“Base Salary”) in accordance with the Company’s payroll practices, including the
withholding of appropriate payroll taxes.

    .

    (b)           The
Employee shall be entitled to participate in all compensation and employee
benefit plans or programs, and to receive all benefits and perquisites, which
are approved by the Board of Directors of the Company and are generally made
available by the Company to all salaried employees of the Company and to the
extent permissible under the general terms and provisions of such plans or
programs and in accordance with the provisions
thereof.  Notwithstanding any of the foregoing, nothing in this
Agreement shall require the Company nor any subsidiary of the Company to
establish, maintain or continue any particular plan or program nor preclude the
amendment, rescission or termination of any such plan or program that may be
established from time to time.  You will be entitled to participate in
any medical, health and insurance plans of the Company commencing 90 days after
the Commencement Date.

    

    
      
         

      

      
        - 1
-

        
          

        

      

      
         

      

    

    (c
)           The Employee
shall be entitled to a monthly car allowance equal to $1,000 payable monthly and
to a quarterly bonus equal to $6,000 payable on the last day of each fiscal
quarter; provided that the first such quarterly payment shall be prorated based
on the time between the Commencement Date and Decembber 31, 2009 and shall be
payable on December 31, 2009.

    

    (c)           On
the Commencement Date Employee shall be granted an option (the “Option”) to
purchase 250,000 shares of Company common stock, $.001 par value (the “Common
Stock”) under and subject to all the terms of the Company’s 2009 Equity
Compensation Plan (“2009 ECP”) at a per share exercise price equal to the
closing price of the Common Stock on the date of grant which shall become vested
and exercisable (i) as to 25,000 shares on the Commencement Date; (ii) as to
25,000 shares on the date of the Company’s filing of its Annual Report on Form
10-K for the year ended December 31, 2009; (iii) as to 100,000 shares on the one
year anniversary of the Commencement Date; and (iv) as to 100,000 shares
on  the two year anniversaryof the Commencement Date

    

    Section 4. Business
Expenses.  The Company shall
pay or reimburse the Employee for all reasonable travel (it being understood
that travel shall be arranged by the Company) and other reasonable expenses
incurred by the Employee in connection with the performance of his duties and
obligations under this Agreement, subject to the Employee’s presentation of
appropriate vouchers in accordance with such expense account policies and
approval procedures as the Company may from time to time establish for employees
(including but not limited to prior approval of extraordinary expenses) and to
preserve any deductions for Federal income taxation purposes to which the
Company may be entitled.

    

    Section 5.  Termination of
Employment.

    

    (a)           The
Company may terminate Employee’s employment prior to the end of the Term
immediately upon written notice to Employee and will pay the employee for 30
days post termination date.  Employee may terminate Employee’s
employment upon thirty days’ prior written notice to the Company.  In
the event that the Employee’s employment terminates prior to expiration of the
Term due to any reason, earned but unpaid Base Salary as of the date of
termination of employment shall be payable in
full.    However, no other payments shall be made, or
benefits provided, by the Company under this Agreement except as otherwise
required by law.

    

    
      
         

      

      
        - 2
-

        
          

        

      

      
         

      

    

    Section 6.  Confidentiality;
Covenant Against Competition; Proprietary Information;
Lock-up.

     

    (a)           The
Employee shall execute the Confidentiality, Non-Compete and Inventions
Assignment Agreement attached hereto as Attachment A concurrently with the
execution of this Agreement.

     

    (b)      Without
the prior written consent of the Company, Employee will not, directly or
indirectly, offer, sell, pledge, contract to sell (including any short sale),
grant any option to purchase or otherwise dispose of any shares of Common Stock
or other Company securities (including, without limitation, shares of Common
Stock of the Company which may be deemed to be beneficially owned by the
undersigned on the date hereof in accordance with the rules and regulations of
the Securities and Exchange Commission, shares of Common Stock which may be
issued upon exercise of a stock option or warrant and any other security
convertible into or exchangeable for Common Stock) (each of the foregoing
referred to as a “Disposition”) from the date hereof until April 29,
2009

     

    

    Section 7.  Withholding
Taxes.  The Company may
directly or indirectly withhold from any payments made under this Agreement all
Federal, state, city or other taxes and all other deductions as shall be
required pursuant to any law or governmental regulation or ruling or pursuant to
any contributory benefit plan maintained by the Company in which the Employee
may participate.

    

    Section 8.  Notices.  All notices,
requests, demands and other communications required or permitted hereunder shall
be given in writing and shall be deemed to have been duly given if delivered or
mailed, postage prepaid, by certified or registered mail or by use of an
independent third party commercial delivery service for same day or next day
delivery and providing a signed receipt as follows:

    

    (a)           To
the Company:

    NeoStem, Inc.

    420 Lexington Avenue

    Suite 450

    New York, New
York  10170

    Attention:  General
Counsel

    

    (b)           To
the Employee:

    Christopher Duignan

    

    or to
such other address as either party shall have previously specified in writing to
the other.  Notice by mail shall be deemed effective on the second
business day after its deposit with the United States Postal Service, notice by
same day courier service shall be deemed effective on the day of deposit with
the delivery service and notice by next day delivery service shall be deemed
effective on the day following the deposit with the delivery
service.

    

    Section 9.  No
Attachment.  Except as
required by law, no right to receive payments under this Agreement shall be
subject to anticipation, commutation, alienation, sale, assignment, encumbrance,
charge, pledge, or hypothecation or to execution, attachment, levy, or similar
process or assignment by operation of law, and any attempt, voluntary or
involuntary, to effect any such action shall be null, void and of no effect;
provided, however, that
nothing in this Section 9 shall preclude the assumption of such rights by
executors, administrators or other legal representatives of the Employee or her
estate and their conveying any rights hereunder to the person or persons
entitled thereto.

    

    
      
         

      

      
        - 3
-

        
          

        

      

      
         

      

    

    Section 10.  Source of
Payment.  All payments
provided for under this Agreement shall be paid in cash from the general funds
of the Company.  The Company shall not be required to establish a
special or separate fund or other segregation of assets to assure such payments,
and, if the Company shall make any investments to aid it in meeting its
obligations hereunder, the Employee shall have no right, title or interest
whatever in or to any such investments except as may otherwise be expressly
provided in a separate written instrument relating to such
investments.  Nothing contained in this Agreement, and no action taken
pursuant to its provisions, shall create or be construed to create a trust of
any kind, or a fiduciary relationship, between the Company and the Employee or
any other person.  To the extent that any person acquires a right to
receive payments from the Company hereunder, such right, without prejudice to
rights which employees may have, shall be no greater than the right of an
unsecured creditor of the Company.

    

    Section 11.  Binding
Agreement; No Assignment.  This Agreement
shall be binding upon, and shall inure to the benefit of, the Employee and the
Company and their respective permitted successors, assigns, heirs, beneficiaries
and representatives.  This Agreement is personal to the Employee and
may not be assigned by her.  This Agreement may not be assigned by the
Company except (a) in connection with a sale of all or substantially all of its
assets or a merger or consolidation of the Company, or (b) to an entity that is
a subsidiary or affiliate of the Company.  Any attempted assignment in
violation of this Section 11 shall be null and void.

     

    Section 12.  Governing Law;
Consent to Jurisdiction.  The validity,
interpretation, performance, and enforcement of this Agreement shall be governed
by the laws of the State of New York.  In addition, the Employee and
the Company irrevocably submit to the jurisdiction of the courts of the State of
New York and the United States District Court sitting in New York County for the
purpose of any suit, action, proceeding or judgment relating to or arising out
of this Agreement and the transactions contemplated hereby.  Service
of process in connection with any such suit, action or proceeding may be served
on the Employee or the Company anywhere in the world by the same methods as are
specified for the giving of notices under this Agreement.  The
Employee and the Company irrevocably consent to the jurisdiction of any such
court in any such suit, action or proceeding and to the laying of venue in such
court.

    

    Section 13.  Amendments.  This Agreement
may only be amended or otherwise modified by a writing executed by all of the
parties hereto.

    

    Section 14.  Counterparts. This Agreement may be
executed in any number of counterparts, each of which when executed shall be
deemed to be an original and all of which together shall be deemed to be one and
the same instrument.

    

    
      
         

      

      
        - 4
-

        
          

        

      

      
         

      

    

    IN WITNESS WHEREOF, the Company has
caused this Agreement to be executed by its duly authorized officer and the
Employee has signed this Agreement, all as of the

    first
date above written.

    

       

      
        	 	      
                NEOSTEM,
      INC.

                

                

                By:
      /s/ Robin L. Smith

                  Name:  Robin L.
      Smith

                  Title:  Chairman
      and CEO

                 

                

                

                  /s/ Christopher
      Duignan

                  Christopher
      Duignan

                

              

      

       

    

     

     

    Attachment
A

    

    NEOSTEM,
INC.

    

    Confidentiality, Proprietary
Information

    and Inventions
Agreement

    

    

    I
recognize that NeoStem, Inc., a Delaware corporation (the “Company”), is engaged
in the business of operating a commercial autologous adult stem cell bank and
the pre-disease collection, processing and long-term storage of adult stem cells
and the research on very small embryonic like (VSEL) stem cells and other adult
stem cell initiatives both within the U.S. and China (the
“Business”).  Any company with which the Company enters into, or seeks
or considers entering into, a business relationship in furtherance of the
Business is referred to as a “Business Partner”.

     

    I
understand that as part of my performance of duties as an employee of the
Company, I will have access to confidential or proprietary information of the
Company and the Business Partners, and I may make new contributions and
inventions of value to the Company.  I further understand that because
of my relationship to the Company I have created in me a duty of trust and
confidentiality to the Company with respect to any information: (1) related,
applicable or useful to the business of the Company, including the Company’s
anticipated research and development or such activities of its Business
Partners; (2) resulting from tasks performed by me for the Company; (3)
resulting from the use of equipment, supplies or facilities owned, leased or
contracted for by the Company; or (4) related, applicable or useful to the
business of any partner, client or customer of the Company, which may be made
known to me or learned by me during the period of my employment.

     

    
      
         

      

      
        - 5
-

        
          

        

      

      
         

      

    

    For
purposes of this Agreement, the following definitions apply:

     

    “Proprietary
Information” shall mean information relating to the Business or the business of
any Business Partner and generally unavailable to the public that has been
created, discovered, developed or otherwise has become known to the Company or
in which property rights have been assigned or otherwise conveyed to the Company
or a Business Partner, which information has economic value or potential
economic value to the business in which the Company is or will be
engaged.  Proprietary Information shall include, but not be limited
to, trade secrets, processes, formulas, writings, data, know-how, negative
know-how, improvements, discoveries, developments, designs, inventions,
techniques, technical data, patent applications, customer and supplier lists,
financial information, business plans or projections and any modifications or
enhancements to any of the above.

     

    “Inventions”
shall mean all Business-related discoveries, developments, designs,
improvements, inventions, formulas, software programs, processes, techniques,
know-how, negative know-how, writings, graphics and other data, whether or not
patentable or registrable under patent, copyright or similar statutes, that are
related to or useful in the business or future business of the Company or its
Business Partners or result from use of premises or other property owned, leased
or contracted for by the Company.  Without limiting the generality of
the foregoing, Inventions shall also include anything related to the Business
that derives actual or potential economic value from not being generally known
to the public or to other persons who can obtain economic value from its
disclosure or use.

     

    As part
of the consideration for my employment or continued employment, as the case may
be, and the compensation received by me from the Company from time to time, I
hereby agree as follows:

     

    1.           Proprietary Information and
Inventions.

    

    (a)  All
Proprietary Information and Inventions related to the Business shall be the sole
property of the Company and its assigns, and the Company or its Business
Partners, as the case may be, and their assigns shall be the sole owner of all
patents, trademarks, service marks, copyrights and other rights (collectively
referred to herein as “Rights”) pertaining to Proprietary Information and
Inventions.  I hereby assign to the Company any rights I may have or
acquire in Proprietary Information or Inventions or Rights pertaining to the
Proprietary Information or Inventions which Rights arise in the course of my
Employment.  I further agree as to all Proprietary Information or
Inventions to which Rights arise in the course of my Employment to assist the
Company or any person designated by it in every proper way (but at the Company’s
expense) to obtain and from time to time enforce Rights relating to said
Proprietary Information or Inventions in any and all countries.  I
will execute all documents for use in applying for, obtaining and enforcing such
Rights in such Proprietary Information or Inventions as the Company may desire,
together with any assignments thereof to the Company or persons designated by
it.  My obligation to assist the Company or any person designated by
it in obtaining and enforcing Rights relating to Proprietary Information or
Inventions shall continue beyond the cessation of my employment.  In
the event the Company is unable, after reasonable effort, to secure my signature
on any document or documents needed to apply for or enforce any Right relating
to Proprietary Information or to an Invention, whether because of my physical or
mental incapacity or for any other reason whatsoever, I hereby irrevocably
designate and appoint the Company and its duly authorized officers and agents as
my agents and attorneys-in-fact to act for and in my behalf and stead in the
execution and filing of any such application and in furthering the application
for and enforcement of Rights with the same legal force and effect as if such
acts were performed by me.  I hereby acknowledge that all original
works of authorship that are made by me (solely or jointly with others) within
the scope of my employment and which are protectable by copyright are “works for
hire” as that term is defined in the United States Copyright Act (17 USCA,
Section 101).

    

    
      
         

      

      
        - 6
-

        
          

        

      

      
         

      

    

    2.           Confidentiality.  At
all times, both during my employment and after the cessation of my employment,
whether the cessation is voluntary or involuntary, for any reason or no reason,
or by disability, I will keep in strictest confidence and trust all Proprietary
Information, and I will not disclose or use or permit the use or disclosure of
any Proprietary Information or Rights pertaining to Proprietary Information, or
anything related thereto, without the prior written consent of the Company,
except as may be necessary in the ordinary course of performing my duties for
the Company.  I recognize that the Company has received and in the
future will receive from third parties (including Business Partners) their
confidential or proprietary information subject to a duty on the Company’s part
to maintain the confidentiality of such information and to use it only for
certain limited purposes.  I agree that I owe the Company and such
third parties (including Business Partners), during my employment and
thereafter, a duty to hold all such confidential or proprietary information in
the strictest confidence, and I will not disclose or use or permit the use or
disclosure of any such confidential or proprietary information without the prior
written consent of the Company, except as may be necessary in the ordinary
course of performing my duties for the Company consistent with the Company’s
agreement with such third party.

    

    3.           Noncompetition and
Nonsolicitation.  During my employment, and for a period of two
(2) years after the Cessation of my employment, I will not directly or
indirectly, whether alone or in concert with others or as a partner, officer,
director, consultant, agent, employee or stockholder of any company or
commercial enterprise, directly or indirectly, engage in any activity in the
United States, Canada or China that the Company shall determine in good faith is
in competition with the Company concerning its work in the
Business.  During my employment and for a period of two (2) years
after the cessation of my employment, I will not, either directly or indirectly,
either alone or in concert with others, solicit or encourage any employee of or
consultant to the Company to leave the Company or engage directly or indirectly
in competition with the Company in the Business.  During my employment
and for a period of two (2) years after the cessation of my employment, I agree
not to plan or otherwise take any preliminary steps, either alone or in concert
with others, to set up or engage in any business enterprise that would be in
competition with the Company in the Business.  The following shall not
be deemed to be competitive with the Company: (i) my ownership of stock,
partnership interests or other securities of any entity not in excess of two
percent (2%) of any class of such interests or securities which is publicly
traded.  It is understood and agreed that the restrictions contained
in this Section 3 shall immediately cease to be of force and effect in the event
the Company ceases to be engaged in the Business.

    

    
      
         

      

      
        - 7
-

        
          

        

      

      
         

      

    

    4.           Delivery of Company Property and Work
Product.  In the event of the cessation of my employment, I
will deliver to the Company all biological materials, devices, records,
sketches, reports, memoranda, notes, proposals, lists, correspondence,
equipment, documents, photographs, photostats, negatives, undeveloped film,
drawings, specifications, tape recordings or other electronic recordings,
programs, data, marketing material and other materials or property of any nature
belonging to the Company or its clients or customers, and I will not take with
me, or allow a third party to take, any of the foregoing or any reproduction of
any of the foregoing.

    

    5.           No Conflict.  I
represent, warrant and covenant that my performance of all the terms of this
Agreement and the performance of my duties for the Company does not and will not
breach any agreement to keep in confidence proprietary information acquired by
me in confidence or in trust prior to my employment.  I have not
entered into, and I agree that I will not enter into, any agreement, either
written or oral, in conflict herewith.

    

    6.           No Use of Confidential
Information.  I represent, warrant and covenant that I have not
brought and will not bring with me to the Company or use in my employment any
materials or documents of a former employer, or any person or entity for which I
have acted as an independent contractor or consultant, that are not generally
available to the public, unless I have obtained written authorization from any
such former employer, person or firm for their possession and use.  I
understand and agree that, in my service to the Company, I am not to breach any
obligation of confidentiality that I have to former employers or other
persons.

    

    7.           Equitable Relief.  I
acknowledge that irreparable injury may result to the Company from my violation
or continued violation of the terms of this Agreement and, in such event, I
expressly agree that the Company shall be entitled, in addition to damages and
any other remedies provided by law, to an injunction or other equitable remedy
respecting such violation or continued violation by me.

    

    8.           Severability.  If
any provision of this Agreement shall be determined by any court of competent
jurisdiction to be unenforceable or otherwise invalid as written, the same shall
be enforced and validated to the extent permitted by law.  All
provisions of this Agreement are severable, and the unenforceability or
invalidity of any single provision hereof shall not affect the remaining
provisions.

    

    9.           Miscellaneous.  This
Agreement shall be governed by and construed under the laws of the State of New
York applied to contracts made and performed wholly within such
state.  No implied waiver of any provision within this Agreement shall
arise in the absence of a waiver in writing, and no waiver with respect to a
specific circumstance, event or occasion shall be construed as a continuing
waiver as to similar circumstances, events or occasions.  This
Agreement, together with the Consulting Agreement dated this date, contains the
sole and entire agreement and understanding between the Company and myself with
respect to the subject matter hereof and supersedes and replaces any prior
agreements to the extent any such agreement is inconsistent
herewith.  This Agreement can be amended, modified, released or
changed in whole or in part only by a written agreement executed by the Company
and myself.  This Agreement shall be binding upon me, my heirs,
executors, assigns and administrators, and it shall inure to the benefit of the
Company and each of its successors or assigns.  This Agreement shall
be effective as of the first day of my being retained to render services to the
Company, even if such date precedes the date I sign this Agreement.

    

    
      
         

      

      
        - 8
-

        
          

        

      

      
         

      

    

    10.           Thorough Understanding of
Agreement.  I have read all of this Agreement and understand it
completely, and by my signature below I represent that this Agreement is the
only statement made by or on behalf of the Company upon which I have relied in
signing this Agreement.

    

    IN WITNESS WHEREOF, I have caused this
Agreement to be signed on the date written below.

     

    

    DATED:  November
19, 2009

    

    Employee:

    

    

    /s/
Christopher Duignan

    Christopher
Duignan

     

    
      
         

      

        
        - 9
-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00171-of-00352.parquet"}]]